News | April 03, 2026
Cardinal Health boosts production of cutting-edge cancer therapy ingredient
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
18-year veteran Saharsh will position the CDMO as a premier global API process development and commercial manufacturing specialist
Enthral.ai’s platform integrates AI-driven capabilities with compliance-first architecture, enabling automated training workflows
This marks a meaningful step in the company's continued expansion in the region
Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina
The center brings together hands on technology demonstrations, application expertise, and commercial operations
The new regimen, delivering 50 mg/5 mL and 28 mg/5 mL doses, offers a higher concentration of the drug for both loading and maintenance phases
Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume
The CDMO Leadership Awards spotlight top-performing development and manufacturing service providers
The new assay consolidates screening for four major viral threats into a single workflow
Subscribe To Our Newsletter & Stay Updated
